Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 44Squamous Cell Carcinoma of Head and Neck 23Carcinoma, Non-Small-Cell Lung 23Head and Neck Neoplasms 13Pancreatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Squamous Cell 8Neoplasms 7Lung Neoplasms 7Colonic Neoplasms 7Rectal Neoplasms 6Esophageal Neoplasms 5Carcinoma 5Recurrence 4Carcinoma, Renal Cell 4Stomach Neoplasms 3Neoplasms, Squamous Cell 3Hereditary Sensory and Autonomic Neuropathies 3Glioblastoma 3Gastrointestinal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colorectal Cancer Metastatic 3Breast Neoplasms 3Tongue Neoplasms 2Sarcoma 2Salivary Gland Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Melanoma 2Glioma 2

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Cetuximab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡